Equity / Investment · MENA · Announced 30 Jul 2024
Immuneel Therapeutics → Taiba Healthcare
Equity / Investment deal between Immuneel Therapeutics (India) and Taiba Healthcare (Oman), covering IMN-003A, announced 30 Jul 2024. Value: $12m.
Parties: Immuneel Therapeutics (India) → Taiba Healthcare Group (Oman)
- Deal type
- Equity / Investment
- Value
- $12m
- Territory
- aiba's footprint spans the GCC and broader Middle East & Africa (Muscat HQ, regional MENA offices); Immuneel develops and manufactures in India. The therapy is intended for affordable access across developing markets in MEA.
- Therapeutic area
- Oncology
- Asset
- IMN-003A — an autologous CD19-targeted CAR-T cell therapy for B-cell leukemias and lymphomas; Immuneel's lead product, positioned at roughly one-tenth the cost of comparable Western CAR-T therapies. The investment specifically funds its first Phase 2 trial.
- Announced
- 30 Jul 2024
Our analysis
Why this matters.
In July 2024, Oman's taiba Healthcare Group put $12 million into Immuneel Therapeutics — the Indian CAR-T pioneer founded by Biocon's Kiran Mazumdar-Shaw and oncologist-author Siddhartha Mukherjee.
The full analysis is free to read with a work email on this page.
Source: BusinessWire